PK
Therapeutic Areas
Resolve Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| RSLV-132 | Sjögren's Disease | Phase 2 |
| RSLV-132 / Platform | Polytrauma / SIRS | Observational Study |
Leadership Team at Resolve Therapeutics
JP
James Posada, Ph.D.
Founder, Chief Executive Officer
GI
Gábor Illei, MD, PhD, MHS
Clinical Strategy Leader